In vivo, IL-18 stimulation of human NK cells promoted IFN-γ generation and antibody-dependent cell-mediated cytotoxicity (ADCC) to the lymphoblast-like tumor cell line Raji following treatment with rituximab, making IL-18 a potential cytokine for combination cancer therapy [247]. Here, IL18 is linked to cancer.